Seek

LONDON, November 7, 2011 - Single vaccination effective against all influenza strains Data to be presented at Influenza Congress 2011 USA SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.

LONDON, July 18, 2011 - 90% Reduction in HIV Viral Load Demonstrated Compared With Normal Disease Progression SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

LONDON, December 20, 2010 - A breakthrough drug containing theobromine, an ingredient naturally present in cocoa and chocolate, is entering the final stages of human clinical trials for the treatment of persistent cough, researchers announced today.

LONDON, December 20, 2010 - SEEK, a leading UK privately-owned drug-discovery group,is pleased to announce the establishment of a new joint venture entity with Pernix Therapeutics Holdings, Inc.

LONDON, December 8, 2010 - SEEK, a leading UK privately-owned drug-discovery group, today presented data on the successful conclusion of a Phase I safety and tolerability study for its investigational Universal Influenza Vaccine, FLU-v, at the World Influenza Congress in Amsterdam (7-9 December).